Previous Article | Next Article 
Journal of Clinical Microbiology, May 1999, p. 1518-1523, Vol. 37, No. 5
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Mycoplasma penetrans and Other
Mycoplasmas in Urine of Human Immunodeficiency Virus-Positive
Children
Althaf I.
Hussain,1
William Lane M.
Robson,2
Robin
Kelley,3
Tanya
Reid,4 and
J. David
Gangemi5,*
Department of Microbiology and Molecular
Medicine, Clemson University, Clemson, South
Carolina1; Department of
Pediatric Nephrology2 and Department of
Pediatric Infectious Disease,3 The Children's
Hospital, Greenville Hospital System, and Greenville
Hospital System/Clemson University Biomedical
Cooperative,5 Greenville, South Carolina;
and Children's Immunology Center,4
University of South Carolina School of
Medicine,4 Columbia, South Carolina
Received 18 May 1998/Returned for modification 18 August
1998/Accepted 28 January 1999
 |
ABSTRACT |
Urine samples from children with human immunodeficiency virus (HIV)
infection and healthy controls were examined for mycoplasmas by
culture. Standard biochemical assays, sodium dodecyl
sulfate-polyacrylamide gel electrophoresis, and PCR (16S and 16S-23S
spacer rRNA region) were used for identification of isolates.
Mycoplasmas were identified from 13 (87%) of 15 HIV-positive patients
and 3 (20%) of 15 HIV-negative control patients. The frequency and
type of mycoplasma varied with the severity of HIV infection.
Mycoplasma penetrans, Mycoplasma pirum,
Mycoplasma fermentans, and Mycoplasma
genitalium were isolated from patients with severe
immunodeficiency. Mycoplasma hominis and Ureaplasma
urealyticum were isolated more frequently from children in the
early stages of HIV infection and from HIV-negative patients.
Mycoplasma penetrans was isolated from one (50%) of two
patients in Centers for Disease Control and Prevention (CDC) group B
and from five (55.5%) of nine pediatric patients with AIDS (CDC group
C). This is the first report that indicates that "AIDS-associated" mycoplasmas are more common in HIV-infected children than in HIV-negative controls.
 |
INTRODUCTION |
Mycoplasmas are associated
with a variety of diseases in plants, animals, and humans,
including diseases involving the immune system. The recent isolation of
these organisms from adults with AIDS suggests that mycoplasmas might
be cofactors in patients with AIDS (2, 4, 8, 18, 22, 25, 26, 34,
44). The four species of mycoplasmas identified as being
associated with AIDS ("AIDS-associated" mycoplasmas) include
Mycoplasma fermentans, Mycoplasma pirum,
Mycoplasma genitalium, and Mycoplasma penetrans (26). This study was designed to determine if mycoplasmas
are present in the urine of children who test positive for human
immunodeficiency virus (HIV) and whether the presence of specific
mycoplasmas is correlated with age or degree of immunosuppression.
 |
MATERIALS AND METHODS |
Patient information.
Fifteen children who tested positive
for HIV were identified at the pediatric HIV clinics in Greenville and
Columbia, S.C., and 15 HIV-negative patients were identified at the
pediatric nephrology clinic in Greenville (Table
1). HIV status was determined by PCR for
proviral DNA and immune complex-dissociated p24 antigen assay (enzyme
immunoassay with neutralization) (30). All HIV-positive children were presumed to have acquired HIV from their mother during
pregnancy, delivery, or breast-feeding. The HIV-positive patients were
classified according to the classification system of the Centers for
Disease Control and Prevention (CDC) for HIV infection in children
(5). By that system, infected children are separated into
mutually exclusive categories according to infectious, clinical, and
immunologic status. The immunologic classification is determined by the
age-specific CD4 T-lymphocyte count or the percentage of total
lymphocytes that are CD4 lymphocytes. Categories N, A, B, and C refer
to HIV-positive children with no, mild, moderate, or severe symptoms
and signs, respectively. Children who tested positive for HIV but who
were classified in category E (which includes children who test
positive for HIV due to transplacental antibodies but in whom infection
with HIV is not confirmed) were not included in this study. After
obtaining informed consent, urine specimens were collected from each
HIV-positive child and HIV-negative control. A urine specimen was
obtained from some patients at more than one clinic visit. When more
than one urine specimen was collected, the clinical and laboratory data
at the time of collection of the last urine specimen were used to
classify the child according to the CDC classification system. The
patient information obtained included age, sex, and CDC classification.
The laboratory data included the CD4 count.
Preparation and inoculation of urine sediments for culture.
Urine was collected in a sterile urine container and was transferred to
a 15-ml centrifuge tube and centrifuged at 500 × g for
10 min at 4°C. The pellet was suspended in 1 ml of Friis broth medium, and 100 µl was used to inoculate four broth media (2 ml each
of Friis, SP4, PH, and Hayflicks [HF] broth media) and four agar
plates (Friis, SP4, PH, and HF agar plates) designed to support the
primary isolation of mycoplasmas (13, 43). The supernatant obtained was centrifuged again in a 15-ml centrifuge tube at
2,600 × g for 10 min at 4°C, and the pellet was
resuspended and inoculated into another set of broth and agar plates as
described above. This isolation procedure resulted in the use of 16 separate isolation media for each urine specimen. A urine sample was
defined as the portion of urine used in each of the 16 isolation steps.
The procedures for the processing of the urine specimens and methods
for the isolation of mycoplasmas were designed by Christian T. K. H. Stadtlander.
Isolation of mycoplasmas from culture.
Inoculated broth and
agar plates were incubated at 37°C in the presence of 5%
CO2 (35, 41, 42, 46) for as long as 6 weeks. The
broth cultures were examined frequently for thread-like sediments and
pH change. The agar surfaces were observed with an inverted microscope
for the presence of colonies with a fried-egg appearance.
Sham-inoculated controls were maintained for broth and agar plates for
each batch of media. One milliliter of culture-positive broth was
passed through a 0.2-µm-pore-size Acrodisc filter (Gelman Sciences).
The filtrate (approximately 1 ml) was inoculated into 20 ml of the same
broth and also onto an agar medium. Pieces of 1 cm2 were
cut with a sterile scalpel from agar plates containing individual mycoplasma colonies, transferred first into a 2-ml and then into a
25-ml tissue culture flask containing 20 ml of broth, and incubated in
the presence of 5% CO2. Cultures were observed daily for a color change. Flasks showing a change in color were subcultured in a
petri dish containing solid medium for observation for colony morphologies with a typical fried-egg appearance. The contents of the
flask containing the agar blocks that showed a color change were
filtered through a 0.2-µm-pore-size filter and aliquoted into samples
of 1 ml, and the samples were placed in sterile vials and stored at
80°C. All stocks were passed through the filter by a standard
cloning and filtration procedure. Briefly, the isolates obtained were
filtered through a 0.2-µm-pore-size filter by using a 3-ml syringe
and were cultured on SP4 solid medium, and the isolated colonies were
picked and again inoculated into a broth culture. To obtain the
mycoplasma isolates in pure form for further analysis, the isolates
were subjected to a cloning and filtration procedure as described
previously (41).
Preliminary identification.
Cloned isolates were grown on
SP4 agar medium, and an isolated colony was picked with a sterile
Pasteur pipette. The agar plugs were transferred to 2 ml of SP4 broth,
and the colonies were disrupted by pressing the plug against the wall
of the test tube to release the organisms. The isolates were incubated
for 3 to 5 days at 37°C and were used as stock for all identification procedures. The biochemical identification methods used included glucose utilization, arginine hydrolysis, and urease hydrolysis (1). The test media used were modified versions of those
described previously (43). The test media and appropriate
controls (Mycoplasma arginini ATCC 23714, Mycoplasma
buccale ATCC 23636, M. genitalium ATCC 33530, Mycoplasma hominis ATCC 23114, Mycoplasma
lipophilum ATCC 27104, Mycoplasma orale ATCC 23714, M. pirum ATCC 25960, Mycoplasma pneumoniae ATCC
15531, Mycoplasma primatum ATCC 15497, Mycoplasma
salivarium ATCC 23064, Acholeplasma laidlawii ATCC 23206, and Ureaplasma urealyticum ATCC 27168) were
inoculated with 1 ml of a 24-h broth culture containing approximately
108 CFU/ml and were incubated at 37°C in the presence of
5% CO2 for at least 2 weeks.
SDS-PAGE.
Analysis of the protein profile was performed by
using one-dimensional sodium dodecyl sulfate (SDS)-polyacrylamide gel
electrophoresis (PAGE) (14). The Mycoplasma
pellets were washed three times in 0.25 M NaCl and were resuspended in
phosphate-buffered saline (PBS; pH 7.5), and the protein content was
estimated and adjusted to 1 mg/ml (Bio-Rad, Richmond, Calif.). A
100-µl sample was heated for 3 min with 20 µl of
SDS-2-mercaptoethanol buffer (1 ml of 10% SDS with 20 µl of
2-mercaptoethanol), and 20 µl of the adjusted protein preparation was
electrophoresed in a 10% polyacrylamide gel (Dc protein assay kit;
Bio-Rad) at 200 V for 60 min or until the bromophenol blue dye front
reached the bottom of the gel. The gels were stained with Coomassie
blue or were blotted onto nitrocellulose membranes for Western blot analysis.
Western blot analysis.
The electrophoresed proteins were
transferred from the gel to a nitrocellulose membrane (presoaked in
distilled water) with the Bio-Rad transfer cell at 100 V for 1 h.
The nitrocellulose membranes were removed and blocked with 3% bovine
serum albumin in PBS (pH 7.5) on a shaker overnight. After washing
three times in PBS-N (PBS with 0.05% [vol/vol] Nonidet P-40) the
membrane was incubated with primary antibody (see Acknowledgments) at
37°C for 1 h (10, 14). After washing three times in
PBS-N, a horseradish peroxidase-linked secondary antibody (Sigma
Chemical Co., St. Louis, Mo.) was added and the washing and blocking
steps were repeated. The nitrocellulose membrane was treated with
solution A (50 ml of PBS [pH 7.5] and 300 µl of hydrogen peroxide)
and solution B (10 ml of ice-cold methanol and 0.3 g of
horseradish peroxidase color developing reagent [DAB]) for the
detection of proteins.
PCR-based confirmation of mycoplasma species.
One-milliliter
samples of 24-h broth cultures were centrifuged at 15,000 × g for 30 min at 4°C. The pellet was washed three times with PBS
(pH 7.3) and was centrifuged again as described above. The sediment was
suspended in 100 µl of lysis buffer (1 mM EDTA [pH 8.0], 10 mM
Tris-HCl [pH 8.0], 0.1% Triton X-100, 200 µg of proteinase K per
ml). The mixture was incubated at 55°C overnight. The samples were
heated for 5 min at 95°C to inactivate the proteinase K. Ten
microliters of the mixture was used for analysis. Two different PCR
procedures, a two-step PCR used to amplify the intergenic rRNA spacer
regions and the 16S rRNA gene (19, 44) PCR, were used for
confirmation of species. All reactions were performed in 50-µl
volumes. Ten microliters of the second-step PCR product and 15 µl of
the 16S rRNA PCR product were electrophoresed in a 2.0% agarose gel
for 45 to 60 min at 60 V in a Tris-borate buffer (pH 8.0). The gel was
stained with ethidium bromide and the products were visualized with a
UV transilluminator and photographed with a Polaroid camera (Fig.
1 and 2).
Controls consisted of known mycoplasmas (M. salivarium ATCC
23064) obtained from the American Type Culture Collection (ATCC).

View larger version (68K):
[in this window]
[in a new window]
|
FIG. 1.
Agarose gel electrophoresis of the second-step PCR
products. 16S-23S rRNA PCR of intergenic spacer regions of
Mycoplasma species isolated from urine sediments. Ten
microliters of the second-step PCR products was subjected to
electrophoresis in a 2% agarose gel. Lane 1, 50- to 2,000-bp DNA
marker; lane 2, M. pirum; lane 3, M. fermentans;
lane 4, M. penetrans; lane 5, M. hominis; lane 6, M. salivarium ATCC 23064; lane 7, negative control.
|
|

View larger version (100K):
[in this window]
[in a new window]
|
FIG. 2.
Restriction enzyme digestion pattern of the second-step
PCR products. Five microliters of the second-step products was digested
with 1 U of HindIII or VspI, electrophoresed
in a 2% agarose gel, and stained with ethidium bromide. Lanes 1 and 8, 2,000- to 50-bp DNA marker; lanes 2, M. penetrans; lanes 3, M. fermentans; lanes 4, M. genitalium; lanes 5, M. pirum; lanes 6, M. hominis; lanes 7, M. salivarium ATCC 23064, used as a positive control. (A)
HindIII-cleaved PCR products; (B)
VspI-cleaved PCR products.
|
|
Sequence analysis.
The amplified products were analyzed by
cycle sequencing with dye-labeled terminators (ABI PRISM Dye Terminator
Cycle Sequencing Ready Reaction Kits; Perkin-Elmer). The nucleotide
sequences obtained were compared with known mycoplasmal DNA sequences
by searching the databases (GenBank, EMBL, DDBJ, and PDB) by using a
basic and a local alignment search tool (BLAST) and an SRS-Fasta
sequence subset search with default parameters. The database accession numbers of the known mycoplasmas used for comparison are gb/L10839 for
M. penetrans, gb/M24289 for M. fermentans, D14526
for M. genitalium, dbj/D14527 for M. pirum, and
emb/x58559 for M. hominis. The 16S-23S intergenic spacer
rRNA regions and the sequence for the 16S rRNA gene were used for
confirmation of mycoplasma identification (3, 16, 17, 19,
44).
Statistical methods.
Statistical analysis was performed by
using the statistical software package Breeze/STAT. The P
value used was the corrected chi-square test value.
 |
RESULTS |
Preliminary isolation of mycoplasmas was successful with
both centrifugation speeds used for the processing of the urine
samples. However, centrifugation at 500 × g yielded
more frequent isolation (61.1%) than centrifugation at
2,600 × g (38.8%). The summary of the isolation
yields by different criteria is shown in Table 2. Among the four different growth media
used for isolation, SP4, HF, Friis, and PH media accounted for 37.0, 19.2, 19.2, and 24.6% isolation, respectively. The percent isolation
frequency of mycoplasmas from broth medium (51.4%) and solid medium
(48.6%) were not much different. Use of methods such as blind passages and plate washes increased the chances of isolation of mycoplasmas from
cultures negative for mycoplasmas in the first round of isolation attempts.
More than one urine specimen was collected from four HIV-positive
children. Five urine specimens were obtained from one child, four urine
specimens were obtained from one child, and two urine specimens were
obtained from each of the three children. Table 3 presents the age and sex of the
HIV-positive patients in each CDC classification, the mean age of the
patients, and the median CD4 cell count. Glucose utilization,
arginine hydrolysis, and urease hydrolysis test results confirmed the
patterns consistent with the genus Mycoplasma.
SDS-PAGE, Western blotting, and PCR confirmed the presence of
individual Mycoplasma species. Identification of individual
mycoplasma species was consistent between methods (Table
4).
Table 4 presents the data obtained from biochemical tests and DNA
analysis by PCR that was used to identify the species of mycoplasmas
isolated from the HIV-positive pediatric patients. By use of the
results from the preliminary genus identification procedures
recommended by the Subcommittee for the Taxonomy of Mollicutes,
namely, (i) colony appearance (typical fried-egg
appearance), (ii) filterability (isolates can be passed through a
0.2-µm-pore-size filter), (iii) absence of reversion in
antibiotic-free growth medium, and (iv) biochemical
characteristics, and by use of DNA analysis, the identities of the
isolates were confirmed.
Mycoplasmas were isolated from 13 (87%) of 15 children who tested
positive for HIV and from 3 (20%) of 15 HIV-negative controls. The difference was statistically significant (P < 0.001). Table 5 presents the age,
CDC classification, median CD4 count, and Mycoplasma species
for patients from whom more than one mycoplasma was isolated. The
isolation of multiple mycoplasma species from 5 (33%) of 15 HIV-positive patients ranging from ages 2.3 to 11.0 years was random
and did not correlate with the median CD4 counts (Table 5). However,
four (80%) of these five patients had been classified in CDC class C
and, accordingly, showed severe degrees of immunologic suppression. The
distribution of HIV-positive patients according to the degree of
immunologic suppression and CDC classification is presented in Table 6.
Five (33%) of the 15 patients were severely immunosuppressed, 7 (47%) of the 15 patients were classified as moderately
immunosuppressed, and 3 (20%) of the 15 patients showed no signs of
immunosuppression. Table 6 also presents
the distribution of patients according to age and immunologic
suppression: 8 (53%), 6 (40%), and 1 (7%) of the 15 patients
belonged to the age groups of >6, 1 to 5, and <1 year, respectively.
In two urine specimens from HIV-positive children, mycoplasma-like
organisms were observed, but identification was not possible because
repeated attempts at the isolation of pure colonies on agar plates were
hindered due to contamination with other organisms.
View this table:
[in this window]
[in a new window]
|
TABLE 5.
Age, CDC classification, and median CD4 count for
patients from whom more than one Mycoplasma species
was isolated
|
|
M. hominis and U. urealyticum.
M.
hominis and U. urealyticum were identified in the urine
from both HIV-negative controls and HIV-positive children. The difference in the rate of isolation of M. hominis and
U. urealyticum from HIV-positive and HIV-negative controls
was not statistically significant. The average ages of the controls and
the HIV-positive patients from whom M. hominis was isolated
were 7.0 and 9.0 years, respectively. The average ages of the controls
and the HIV-positive patients from whom U. urealyticum was
isolated were 8.0 and 8.4 years, respectively.
AIDS-associated mycoplasmas.
Table
7 presents the frequency of isolation of
Mycoplasma species from controls and from HIV-positive
children according to CDC classification, and Table
8 presents the frequency of isolation of
Mycoplasma species by age. M. penetrans, M. fermentans, M. genitalium, and M. pirum were
isolated only from children with a CDC classification of B or C.
View this table:
[in this window]
[in a new window]
|
TABLE 7.
Mycoplasma species isolated from HIV-negative
controls and HIV-positive children according to CDC
classification
|
|
 |
DISCUSSION |
We identified AIDS-associated mycoplasmas more
frequently from the urine of HIV-positive children than from the
urine of HIV-negative controls (P < 0.001). To our
knowledge, this study is the first to report the identification of
AIDS-associated mycoplasmas in the urine of HIV-positive children.
Mycoplasma isolation (culture) is notoriously difficult and requires
screening of multiple urine samples in a variety of media. Although
difficult and laborious, direct isolation is considered the "gold
standard" for the detection of these organisms. This is in contrast
to techniques such as PCR, which provide only indirect evidence
(19).
The species distribution of mycoplasmas isolated from HIV-positive and
HIV-negative children was different. None of the AIDS-associated mycoplasmas were isolated from HIV-negative children. Only M. hominis and U. urealyticum were isolated from these
children. These mycoplasmas are commensal hosts of the urogenital
tracts of women (15). As many as 80% of sexually
active asymptomatic women are colonized with U. urealyticum (6, 7, 38). Younger age, lower
socioeconomic status, sexual activity with multiple partners, and oral
contraceptive use are associated with increased rates of colonization
(6, 7). Vertical transmission of mycoplasmas from the
genital tract of the mother can occur either in utero or at delivery
(7, 38, 45). The rate of transmission to full-term infants
born to colonized mothers is 45 to 66% (7, 38).
Colonization of infants is reported to be transient, with isolation
rates decreasing after 3 months of age, although preterm infants might
carry these organisms in the respiratory tract for several months
(45). The ages of the three HIV-negative controls from whom
M. hominis or U. urealyticum was isolated were
8.0, 10.0, and 11.0 years, respectively. It is possible that the
M. hominis and U. urealyticum organisms
identified in the HIV-negative children in our study reflect the
persistence of these organisms from the newborn period. Several of the
HIV-negative controls were adolescents, and it is possible that they
were sexually active, which might provide an alternate explanation for
the presence of these organisms. M. hominis and U. urealyticum were isolated more commonly from HIV-positive
children, although the result was not statistically significant. As
with infection due to M. hominis and U. urealyticum, HIV infection is more frequent in mothers of younger
age and lower socioeconomic status and in those who are sexually active
with multiple partners. Vertical transmission of HIV to the child of an
HIV-positive mother is possible in utero, during delivery, and with
breast-feeding (39). It is possible that HIV and these
mycoplasmas are vertically transmitted at similar times during
gestation or delivery.
M. penetrans and other AIDS-associated mycoplasmas were
identified only from older HIV-positive children with a CDC
classification of B or C. AIDS-associated mycoplasmas were not
identified in the urine of the single HIV-positive child who was under
the age of 1 year or from the four HIV-positive children with a CDC
classification of N or A. It is possible that we did not identify
AIDS-associated mycoplasmas in HIV-positive children under the age of 1 year or in those with a CDC classification of N or A because of the
small number of patients in our study.
M. penetrans was isolated from 6 (54.5%) of the 11 children
with a CDC classification of B or C and 5 (55.5%) of the 9 children with a CDC classification of C. M. penetrans was isolated
from more than one urine specimen from two of the HIV-positive
patients. Both patients were over 1 year of age and had CDC
classifications of B and C, respectively. M. penetrans was
isolated in the last two of four urine specimens from one patient and
the last four of the five urine specimens from the other patient. The
ages of the first patient at the times of collection of the four urine specimens were 2.0, 2.1, 2.2, and 2.3 years, respectively. The ages of
the second patient were 8.7, 8.8, 8.9, 9.0, and 9.8 years, respectively. Little is known about the temporal relationship of
AIDS-associated mycoplasmas to infection with HIV. The data for these
two patients suggest that M. penetrans is acquired after birth by children who acquire HIV perinatally and persists in the urine
for as long as 1.0 year.
Unidentifiable mycoplasmas were found in the urine of two of the
HIV-positive children. This raises the possibility of as yet
undiscovered Mycoplasma species in patients with AIDS. It is
also possible that the unidentified mycoplasmas were known species not
considered to be human pathogens.
There are numerous reports of the isolation of AIDS-associated
mycoplasmas from HIV-positive adults (8, 18, 20, 21). In
most studies, these species are isolated more frequently from HIV-positive adults than from controls (8, 18). These
observations suggest that mycoplasmas might be a cofactor or a
copathogen in the pathogenesis of AIDS. The term "cofactor" implies
that an AIDS-associated mycoplasma acts synergistically with HIV in the pathogenesis of AIDS, whereas the term "copathogen" implies that infection with an AIDS-associated mycoplasma requires both HIV infection and associated immunodeficiency. Our study confirms that
AIDS-associated mycoplasmas are more common in HIV-positive children
than in HIV-negative controls and therefore provides modest support for
the hypothesis that these mycoplasmas might be cofactors or copathogens
in children with AIDS. Numerous reports support this possibility
(4, 27-29, 31, 33, 34, 37, 40). The variation in the time
between the acquisition of HIV infection and the development of
symptoms and signs of disease and the low frequency of HIV-infected
lymphocytes in the peripheral blood of infected individuals suggest the
possibility of alternate factors. Mycoplasmas might act as a cofactor
by enhancing virus replication or accelerating disease progression
(9, 22). The idea is supported by the observation that
treatment of HIV-infected cell cultures with tetracycline analogues
active against mycoplasmas inhibits cell killing without affecting
virus replication and that certain mycoplasmas enhance the cytopathic
changes brought about by HIV (9, 23, 24, 27). As well,
M. fermentans is reported to enhance the in vitro cytopathic
effect in CEM and U937 cells (24). Additionally, mycoplasmas
have been shown in vitro to be powerful immunomodulators that induce
the activation of B or T lymphocytes, to stimulate cytokine secretion
by several cell types, and to produce superantigens (4, 12,
25, 32, 37). Furthermore, mycoplasma adhesion peptide has
biologic similarities to CD4 and class II major histocompatibility
complex proteins (36).
In conclusion, Mycoplasma species were identified in the
urine of HIV-positive children. AIDS-associated mycoplasmas were found
statistically more frequently in the urine of HIV-positive children
than in the urine of HIV-negative controls. M. penetrans was
the most frequently isolated AIDS-associated mycoplasma and was found
in 45% of the children with a CDC classification of B or C and 55.5%
of the children with a CDC classification of C.
 |
ACKNOWLEDGMENTS |
This work was supported by a grant from the Greenville Hospital
System/Clemson University Biomedical Cooperative. Reagents were
obtained through the AIDS Research and Reference Program, Division of
AIDS, National Institute of Allergy and Infectious Diseases. The
M. hominis monoclonal antibody (monoclonal antibody 10A4.11)
was obtained from H. Watson and G. Cassell; M. penetrans, M. pirum, and M. genitalium antisera were
obtained from Ricardo Rosenbusch, and M. fermentans
antiserum was obtained from J. G. Tully.
We thank Missy Hathcox for assistance in preparation of the manuscript.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Hollings Cancer
Center, Prevention and Control, 261 Calhoun St., Suite 302, P.O. Box 250187, Clemson, SC 29425. Phone: (843) 876-1561. Fax: (843) 876-1963. E-mail: gangemij{at}musc.edu.
 |
REFERENCES |
| 1.
|
Aluotto, B. B.,
R. G. Wittler,
C. O. Williams, and J. E. Faber.
1970.
Standardized bacteriologic techniques for the characterization of Mycoplasma species.
Int. J. Syst. Bacteriol.
20:35-58[Abstract/Free Full Text].
|
| 2.
|
Bauer, F. A.,
D. J. Wear,
P. Angritt, and S.-C. Lo.
1991.
Mycoplasma fermentans (incognitus strain) infection in the kidneys of patients with aquired immunodeficiency syndrome and associated nephropathy: a light microscopic, immunohistochemical, and ultrastructural study.
Hum. Pathol.
22:63-69[Medline].
|
| 3.
|
Behbahani, N.,
A. Blanchard,
G. H. Cassell, and L. Montagnier.
1993.
Phylogenetic analysis of Mycoplasma penetrans, isolated from HIV-infected patients.
FEMS Microbiol. Lett.
109:63-66[Medline].
|
| 4.
|
Blanchard, A., and L. Montagnier.
1994.
AIDS-associated mycoplasmas.
Annu. Rev. Microbiol.
48:687-712[Medline].
|
| 5.
|
Caldwell, M. B.,
M. J. Oxtoby,
R. J. Simonds,
M. L. Lindegren,
M. F. Rogers, and the Centers for Disease Control and Prevention.
1994.
Revised classification system for human immunodeficiency virus infection in children less than 13 years of age.
Morbid. Mortal. Weekly Rep.
43(No. RR-12):1-10.
|
| 6.
|
Carey, J. C.,
W. C. Blackwelder,
R. P. Nugent,
M. A. Matteson,
A. V. Rao,
D. A. Eschenbach,
M. L. F. Lee,
P. J. Rettig,
J. A. Regan,
K. L. Geromanos,
D. H. Martin,
J. G. Pastorek,
R. S. Gibbs,
K. A. Lipscomb, and the Vaginal Infections and Prematurity Study Group.
1991.
Antepartum cultures for Ureaplasma urealyticum are not useful in predicting pregnancy outcome.
Am. J. Obstet. Gynecol.
164:728-733[Medline].
|
| 7.
|
Cassell, G. H.,
K. B. Waites,
H. L. Watson,
D. T. Crouse, and R. Harasawa.
1993.
Ureaplasma urealyticum intrauterine infection: role in prematurity and disease in newborns.
Clin. Microbiol. Rev.
6:69-87[Abstract/Free Full Text].
|
| 8.
|
Chirgwin, K. D.,
M. C. Cummings,
L. R. DeMeo,
M. Murphy, and W. M. McCormack.
1993.
Identification of mycoplasmas in urine from persons infected with human immunodeficiency virus.
Clin. Infect. Dis.
17(Suppl.):S264-S266.
|
| 9.
|
Chowdhury, M. I. H.,
T. Munakata,
Y. Koyanagi,
S. Kobayashi,
S. Arai, and N. Yamamoto.
1990.
Mycoplasma can enhance HIV replication in vitro: a possible cofactor responsible for the progression of AIDS.
Biochem. Biophys. Res. Commun.
170:1365-1370[Medline].
|
| 10.
|
Clyde, W. A., Jr.
1983.
Growth inhibition tests.
Methods Mycoplasmol.
1:405-410.
|
| 11.
|
Cole, B. C., and C. L. Atkin.
1991.
The Mycoplasma arthritidis T-cell mitogen, MAM: a model superantigen.
Immunol. Today
12:271-276[Medline].
|
| 12.
|
Feng, S.-H., and S.-C. Lo.
1994.
Induced mouse spleen B-cell proliferation and secretion of immunoglobulin by lipid-associated membrane proteins of Mycoplasma fermentans incognitus and Mycoplasma penetrans.
Infect. Immun.
62:3916-3921[Abstract/Free Full Text].
|
| 13.
|
Freundt, E. A.
1983.
Culture media for classic mycoplasmas.
Methods Mycoplasmol.
1:127-135.
|
| 14.
|
Gallagher, S., and J. A. Smith.
1995.
One-dimensional polyacrylamide gel electrophoresis of proteins.
In
F. M. Ausubel, R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl (ed.), Current protocols in molecular biology. John Wiley & Sons, Inc., New York, N.Y.
|
| 15.
|
Grattard, F.,
B. Soleihac,
B. de Barbeyrac,
C. Bebear,
P. Seffert, and B. Pozzetto.
1995.
Epidemiologic and molecular investigations of genital mycoplasmas from women and neonates at delivery.
Pediatr. Infect. Dis. J.
14:853-858[Medline].
|
| 16.
|
Grau, O.,
R. Kovacic,
R. Griffais,
V. Launay, and L. Montagnier.
1994.
Development of PCR-based assays for the detection of two human mollicute species, Mycoplasma penetrans and M. hominis.
Mol. Cell. Probes
8:139-148[Medline].
|
| 17.
|
Grau, O.,
R. Kovacic,
R. Griffais, and L. Montagnier.
1993.
Development of a selective and sensitive polymerase chain reaction assay for the detection of Mycoplasma pirum.
FEMS Microbiol. Lett.
106:327-334[Medline].
|
| 18.
|
Grau, O.,
B. Slizewicz,
P. Tuppin,
V. Launay,
E. Bourgeois,
N. Sagot,
M. Moynier,
A. Lafeuillade,
H. Bachelez,
J.-P. Clauvel,
A. Blanchard,
E. Bahraoui, and L. Montagnier.
1995.
Association of Mycoplasma penetrans with human immunodeficiency virus infection.
J. Infect. Dis.
172:672-681[Medline].
|
| 19.
|
Harasawa, R.,
H. Mizusawa,
K. Nozawa,
T. Nakagawa,
K. Asada, and I. Kato.
1993.
Detection and tentative identification of dominant mycoplasma species in cell cultures by restriction analysis of the 16S-23S rRNA intergenic spacer regions.
Res. Microbiol.
144:489-493[Medline].
|
| 20.
|
Hayes, M. M.,
H.-H. Foo,
J. Timenetsky, and S.-C. Lo.
1995.
In vitro antibiotic susceptibility testing of clinical isolates of Mycoplasma penetrans from patients with AIDS.
Antimicrob. Agents Chemother.
39:1386-1387[Abstract].
|
| 21.
|
Katseni, V. L.,
C. B. Gilroy,
B. K. Ryait,
K. Ariyoshi,
P. D. Bieniasz,
J. N. Weber, and D. Taylor-Robinson.
1993.
Mycoplasma fermentans in individuals seropositive and seronegative for HIV-1.
Lancet
341:271-273[Medline].
|
| 22.
|
Lancet
1991.
Mycoplasma and AIDS what connection?
Lancet
337:20-22[Medline]. (Editorial.)
|
| 23.
|
Lemaître, M.,
D. Guétard,
Y. Hénin,
L. Montagnier, and A. Zerial.
1990.
Protective activity of tetracycline analogs against the cytopathic effect of the human immunodeficiency viruses in CEM cells.
Res. Virol.
141:5-16[Medline].
|
| 24.
|
Lemaitre, M.,
Y. Henin,
F. Destouesse,
C. Ferrieux,
L. Montagnier, and A. Blanchard.
1992.
Role of mycoplasma infection in the cytopathic effect induced by human immunodeficiency virus type 1 in infected cell lines.
Infect. Immun.
60:742-748[Abstract/Free Full Text].
|
| 25.
|
Lo, S.-C.
1992.
Mycoplasmas and AIDS, p. 525-545.
In
J. Maniloff, R. N. McElhaney, L. R. Finch, and J. B. Baseman (ed.), Mycoplasmas: molecular biology and pathogenesis. American Society for Microbiology, Washington, D.C.
|
| 26.
|
Lo, S.-C.,
M. S. Dawson,
P. B. Newton III,
M. A. Sonoda,
J. W.-K. Shih,
W. F. Engler,
R. Y.-H. Wang, and D. J. Wear.
1989.
Association of the virus-like infectious agent originally reported in patients with AIDS with acute fatal disease in previously healthy non-AIDS patients.
Am. J. Trop. Med. Hyg.
41:364-376.
|
| 27.
|
Lo, S.-C.,
S. Tsai,
J. R. Benish,
J. W. Shih,
D. J. Wear, and D. M. Wong.
1991.
Enhancement of HIV-1 cytocidal effects in CD4+ lymphocytes by the AIDS-associated mycoplasma.
Science
251:1074-1076[Abstract/Free Full Text].
|
| 28.
|
Lo, S.-C.,
D. J. Wear,
J. W.-K. Shih,
R. Y.-H. Wang,
P. B. Newton III, and J. F. Rodriguez.
1993.
Fatal systemic infections of nonhuman primates by Mycoplasma fermentans (incognitus strain).
Clin. Infect. Dis.
17(Suppl. 1):S283-S288.
|
| 29.
|
Lo, S.-C.,
R. Y.-H. Wang,
P. B. Newton III,
N.-Y. Yang,
M. A. Sonoda, and J. W.-K. Shih.
1989.
Fatal infection of silvered leaf monkeys with a virus-like infectious agent (VLIA) derived from a patient with AIDS.
Am. J. Trop. Med. Hyg.
40:399-409.
|
| 30.
|
Miles, S. A.,
E. Balden,
L. Magpantay,
L. Wei,
A. Leiblein,
D. Hofheinz,
G. Toedter,
E. R. Stiehm,
Y. Bryson, and the Southern California Pediatric AIDS Consortium.
1993.
Rapid serologic testing with immune-complex-dissociated HIV p24 antigen for early detection of HIV infection in neonates.
N. Engl. J. Med.
328:297-302[Abstract/Free Full Text].
|
| 31.
|
Minion, F. C., and K. Jarvill-Taylor.
1994.
Membrane-associated hemolysin activities in mycoplasmas.
FEMS Microbiol. Lett.
116:101-106[Medline].
|
| 32.
|
Montagnier, L., and A. Blanchard.
1993.
Mycoplasmas as co-factors in infection due to the human immunodeficiency virus.
Clin. Infect. Dis.
17(Suppl. 1):S309-S315.
|
| 33.
|
Nir-Paz, R.,
S. Israel,
A. Honigman, and I. Kahane.
1995.
Mycoplasmas regulate HIV-LTR-dependent gene expression.
FEMS Microbiol. Lett.
128:63-68[Medline].
|
| 34.
|
Poulin, S. A.,
R. E. Perkins, and R. B. Kundsin.
1994.
Antibiotic susceptibilities of AIDS-associated mycoplasmas.
J. Clin. Microbiol.
32:1101-1103[Abstract/Free Full Text].
|
| 35.
|
Razin, S., and E. A. Freundt.
1989.
The mycoplasmas, p. 740-789.
In
M. P. Bryant, J. G. Holt, N. Pfennig, and J. T. Staley (ed.), Bergey's manual of systematic bacteriology, vol. 1. The Williams & Wilkins Co., Baltimore, Md.
|
| 36.
|
Root-Bernstein, R. S., and S. H. Hobbs.
1991.
Homologies between mycoplasma adhesion peptide, CD4 and class II MHC proteins: a possible mechanism for HIV-mycoplasma synergism in AIDS.
Res. Immunol.
142:519-523[Medline].
|
| 37.
|
Ruuth, E., and F. Praz.
1989.
Interactions between mycoplasmas and the immune system.
Immunol. Rev.
112:133-160[Medline].
|
| 38.
|
Sánchez, P. J., and J. A. Regan.
1987.
Vertical transmission of Ureaplasma urealyticum in full term infants.
Pediatr. Infect. Dis. J.
6:825-828[Medline].
|
| 39.
|
Scarlatti, G.
1996.
Paediatric HIV infection.
Lancet
348:863-868[Medline].
|
| 40.
|
Shibata, K.-I.,
T. Sasaki, and T. Watanabe.
1995.
AIDS-associated mycoplasmas possess phospholipases C in the membrane.
Infect. Immun.
63:4174-4177[Abstract].
|
| 41.
|
Subcommittee on the Taxonomy of Mollicutes.
1979.
Proposal of minimal standards for descriptions of new species of the class Mollicutes.
Int. J. Syst. Bacteriol.
29:172-180.
|
| 42.
|
Tully, J. G.
1995.
Cultivation and morphology, p. 29-33.
In
J. G. Tully (ed.), Molecular and diagnostic procedures in mycoplasmology, vol. 1. Academic Press, Inc., San Diego, Calif.
|
| 43.
|
Tully, J. G.
1993.
General cultivation techniques for mycoplasmas and spiroplasmas.
Methods Mycoplasmol.
1:99-103.
|
| 44.
|
van Kuppeveld, F. J. M.,
J. T. M. van der Logt,
A. F. Angulo,
M. J. van Zoest,
W. G. V. Quint,
H. G. M. Niesters,
J. M. D. Galama, and W. L. G. Melchers.
1992.
Genus- and species-specific identification of mycoplasmas by 16S rRNA amplification.
Appl. Environ. Microbiol.
58:2606-2615[Abstract/Free Full Text].
|
| 45.
|
Waites, K. B.,
D. T. Crouse, and G. H. Cassell.
1993.
Systemic neonatal infection due to Ureaplasma urealyticum.
Clin. Infect. Dis.
17(Suppl. 1):S131-S135.
|
| 46.
|
Whitcomb, R. F.,
J. G. Tully,
J. M. Bové,
J. M. Bradbury,
G. Christiansen,
I. Kahane,
B. C. Kirkpatrick,
F. Laigret,
R. H. Leach,
H. C. Neimark,
J. D. Pollack,
S. Razin,
B. B. Sears, and D. Taylor-Robinson.
1995.
Revised minimum standards for description of new species of the class Mollicutes (division Tenericutes).
Int. J. Syst. Bacteriol.
45:605-612[Abstract/Free Full Text].
|
Journal of Clinical Microbiology, May 1999, p. 1518-1523, Vol. 37, No. 5
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Waites, K. B., Katz, B., Schelonka, R. L.
(2005). Mycoplasmas and Ureaplasmas as Neonatal Pathogens. Clin. Microbiol. Rev.
18: 757-789
[Abstract]
[Full Text]
-
Sasaki, Y., Ishikawa, J., Yamashita, A., Oshima, K., Kenri, T., Furuya, K., Yoshino, C., Horino, A., Shiba, T., Sasaki, T., Hattori, M.
(2002). The complete genomic sequence of Mycoplasma penetrans, an intracellular bacterial pathogen in humans. Nucleic Acids Res
30: 5293-5300
[Abstract]
[Full Text]